Capim, a startup providing Brazilians the choice to purchase now, pay later (BNPL) for dental providers, has raised $26.7 million in Collection A funding, it tells TechCrunch completely.
Based in July 2021 by Marcelo Lutz and Roberto Biselli, who function co-CEOs, São Paulo-based Capim describes itself as a vertical SaaS firm specializing within the dental sector. It claims that its working system helps dentists digitize and handle their clinics, and enhance income.
One of many issues Capim’s software program does, for instance, is assist sufferers ebook appointments digitally at linked clinics. On the BNPL entrance, the corporate says this providing is inexpensive than another like a bank card.
“Not like the frequent follow in Brazil of paying in installments with bank cards — which requires each a bank card restrict and the flexibility to pay inside a restricted variety of installments — usually as much as six or 12 — our answer provides higher flexibility, permitting funds of as much as 36 installments,” Biselli informed TechCrunch. He claims that the rates of interest that Capim costs are 50% decrease than these charged by conventional banks.
Now with its newest capital infusion, Capim plans to increase its monetary choices with a POS (point-of-sale) terminal that can supply clinics considerably decrease service provider low cost charges (MDR) whereas additionally integrating with its SaaS monetary administration module. A service provider low cost fee (MDR) is a payment charged to a enterprise by the corporate that processes its debit and bank card transactions. The terminal will enable clinics to simply accept bank cards, debit playing cards, and PIX (Brazil’s real-time fee system).
The capital may also go towards the event of what the corporate describes as new AI-powered instruments designed to make scientific operations extra environment friendly. The startup additionally plans to speed up its go-to-market technique to increase its community of clinics and sufferers.
Capim’s Collection A spherical was raised in two tranches. Valor Capital and QED Traders co-led the financing, which included participation from present buyers ONEVC, Canary, and NXTP, in addition to new buyers Endeavor, Saison, and Actyus, a fund led by Creditas CEO Sergio Furio. The startup declined to reveal its valuation. In complete it has raised about $29 million, together with a $2.5 million seed spherical when it first launched in July of 2021.
Lutz and Biselli met whereas engaged on their MBAs at INSEAD, the place they received the INSEAD Enterprise Competitors in December 2020. After operating a profitable pilot in early 2021, they formally launched Capim upon finishing their levels.
Increasing entry
Thus far, the startup says it has helped greater than 60,000 Brazilians acquire entry to dental procedures.
Whereas the corporate declined to reveal onerous income figures, Lutz stated it tripled its income in 2024, whereas including greater than 4,000 clinics to its consumer base. It presently serves 6,000 dental clinics and expects to achieve over 10,000 by 12 months’s finish. Capim shouldn’t be but worthwhile however it did “break even” on the finish of final 12 months, the co-founders say.
Capim makes cash in two methods: through SaaS subscriptions, which offer clinics with digital instruments to handle their operations, in addition to the monetary merchandise, which it says helps clinics enhance affected person accessibility and thus, drive extra income.
Presently, Capim has 130 workers, up from 115 a 12 months in the past.
Valor Capital’s Carlos Costa stated his agency was drawn to put money into Capim as a result of the startup “addresses clear challenges confronted by professionals in managing their clinics and in financing and paying for therapies.”
QED Traders’ Mike Packer stated his agency has been following Capim since its early days.
“After watching how rapidly the corporate scaled up with sturdy unit economics, we had been fairly satisfied of early product market match and noticed that early traction as solely the start,” he informed TechCrunch.
